Acucela Doses First Subject In Phase I Trial For Age-Relate

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
Reply to topic
Acucela Doses First Subject In Phase I Trial For Age-Relate
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Thu Jun 05, 2008 8:22 am Reply with quote
Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has dosed the first subject in a Phase I trial for its lead compound ACU-02. The single-site trial is enrolling healthy normal volunteers in a double-masked, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of ACU-02.

Read more...
View user's profileSend private message
Acucela Doses First Subject In Phase I Trial For Age-Relate
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
 Reply to topic  
Forum Map
Site Map